Chronic Inflammation Under the Microscope: New Case-Cohort Study Probes Biomarkers and Postmenopausal Breast Cancer Risk

The relationship between chronic low-grade inflammation and cancer has occupied researchers for decades, but precisely how measurable signs of systemic inflammation translate into risk for specific breast cancer subtypes remains an open and contested question. A new case-cohort analysis published in the British Journal of Cancer set out to address that question directly, examining whether circulating inflammatory biomarkers are associated with the risk of developing oestrogen receptor-positive breast cancer in postmenopausal women. The study, which appeared online on 19 September 2026, adds a carefully designed piece of evidence to a body of literature that has so far produced mixed and sometimes contradictory results.

Inflammation is one of the hallmarks of cancer biology. Long before a tumour becomes clinically detectable, the tumour microenvironment is often populated by immune cells, cytokines and other signalling molecules that can, under certain conditions, support tumour initiation and progression. Epidemiologists have therefore long been interested in whether markers of systemic inflammation measured in the blood, such as C-reactive protein and various circulating cytokines, might serve as early warning signals of future cancer risk. If such associations could be established robustly, they might open the door to risk stratification, earlier surveillance and, ultimately, prevention strategies targeted at women whose inflammatory profiles place them at elevated risk.

Breast cancer is not a single disease but a collection of biologically distinct subtypes, defined in large part by the presence or absence of hormone receptors and by expression of the HER2 protein. Oestrogen receptor-positive tumours are the most common subtype, particularly among postmenopausal women, and their growth is fuelled by oestrogen signalling. Because both inflammation and oestrogen signalling are influenced by shared factors such as adiposity, age and metabolic health, researchers have hypothesised that inflammatory processes may interact with hormonal pathways in ways that are especially relevant to this subtype. Testing that hypothesis requires large, well-characterised cohorts of postmenopausal women followed over long periods, with blood samples collected before any cancer diagnosis.

The case-cohort design adopted by the study is a methodologically important choice. In a classic prospective cohort study, every participant would be followed and their biomarkers measured, an approach that becomes prohibitively expensive when thousands of blood samples must be assayed for multiple inflammatory markers. A case-cohort design offers an efficient alternative: researchers identify all the women in the cohort who went on to develop the cancer of interest, the cases, and compare them with a randomly selected subcohort drawn from the full study population, regardless of disease status. Because the subcohort is randomly sampled, it provides an unbiased estimate of the underlying distribution of biomarker levels in the population at risk, and the resulting statistical models can yield risk estimates that closely approximate those of a full cohort analysis at a fraction of the laboratory cost.

This efficiency comes with analytical subtleties that the researchers had to navigate. Case-cohort analyses require specialised statistical techniques, most commonly variants of the Cox proportional hazards model with weighted pseudo-likelihood approaches, to account for the overlapping structure of the case group and the subcohort. Confounding is a persistent concern in observational biomarker research: systemic inflammation is correlated with body mass index, smoking, physical inactivity, diabetes and a range of other lifestyle and metabolic factors that themselves influence breast cancer risk. A credible analysis must therefore adjust carefully for these covariates, while also considering the possibility that some of the association between inflammation and cancer operates precisely through those intermediary conditions, making over-adjustment as much a hazard as residual confounding.

Timing is another critical consideration. Inflammatory biomarkers measured in blood samples donated years before diagnosis are generally more informative than those measured close to diagnosis, because a developing, undiagnosed tumour can itself elevate circulating inflammatory markers, creating reverse causation. Studies of this kind typically address the problem by excluding cases diagnosed within the first year or two of follow-up, or by demonstrating that associations persist when early diagnoses are removed. The strength of any prospective biomarker study rests on how convincingly it handles this temporal ambiguity, and readers interpreting the findings should pay close attention to the sensitivity analyses the authors report.

The biological rationale linking inflammation specifically to oestrogen receptor-positive disease is worth unpacking. Adipose tissue, particularly visceral fat abundant after menopause, is not merely a passive energy store but an active endocrine organ that secretes pro-inflammatory cytokines and is a major site of oestrogen synthesis in postmenopausal women through the enzyme aromatase. Chronic inflammatory signalling can promote cell proliferation, inhibit apoptosis, stimulate angiogenesis and generate DNA-damaging reactive oxygen species, all of which are processes plausibly relevant to tumour development. At the same time, oestrogen itself modulates immune responses, meaning the two systems are deeply intertwined. Disentangling whether inflammation independently predicts hormone receptor-positive breast cancer, or merely tracks along with adiposity and metabolic dysfunction, is precisely the kind of question a well-powered case-cohort analysis is positioned to address.

For the wider field, the significance of the study lies less in any single risk estimate than in the accumulation of evidence across diverse populations and designs. Previous prospective investigations of inflammatory markers and breast cancer have reported inconsistent findings, with some observing modest positive associations for overall or hormone receptor-defined disease and others finding little or no association once body size was accounted for. These inconsistencies may reflect differences in the biomarkers measured, the assays used, the length of follow-up, the degree of postmenopausal hormone therapy use in the underlying populations, or genuine heterogeneity across populations. Each new, rigorously conducted analysis helps to narrow the range of plausible effects and to identify the conditions under which inflammatory biomarkers do or do not add predictive value beyond established risk factors.

Clinically, the stakes are considerable. Breast cancer risk prediction models currently rely on combinations of demographic, reproductive, hormonal and familial factors, and increasingly on polygenic risk scores. If validated inflammatory biomarkers were shown to meaningfully improve risk discrimination, they could help identify postmenopausal women who might benefit from intensified screening, lifestyle interventions aimed at reducing systemic inflammation, or, in selected high-risk groups, preventive endocrine therapy. Conversely, if inflammatory markers add little once adiposity and metabolic health are fully accounted for, that too is an important result, redirecting attention toward the modifiable upstream factors that drive both inflammation and cancer risk.

The study also underscores a broader lesson in modern cancer epidemiology: subtype matters. Pooling all breast cancers together can dilute or mask associations that are specific to particular molecular subgroups, and analyses restricted to oestrogen receptor-positive disease represent a step toward the kind of aetiological precision the field increasingly demands. As researchers continue to mine pre-diagnostic blood samples with ever more sensitive multiplex assays, including measures of chronic immune activation and emerging markers of inflammageing, studies of this design will remain central to determining whether the inflammatory fingerprint measurable in a routine blood draw can ever become part of practical cancer risk assessment. For now, the new case-cohort analysis offers a methodologically sound contribution to that ongoing effort, and a reminder that the biology linking inflammation, hormones and cancer is as intricate as it is important.

Subject of Research: Association between circulating inflammatory biomarkers and the risk of postmenopausal oestrogen receptor-positive breast cancer

Article Title: Inflammatory biomarkers and risk of postmenopausal oestrogen receptor-positive breast cancer: a case-cohort analysis

Article References: Inflammatory biomarkers and risk of postmenopausal oestrogen receptor-positive breast cancer: a case-cohort analysis. (n.d.). https://doi.org/10.1038/s41416-026-03624-6

Image Credits: AI Generated

DOI: 10.1038/s41416-026-03624-6

Keywords: inflammatory biomarkers, breast cancer, postmenopausal women, oestrogen receptor-positive, case-cohort analysis, C-reactive protein, chronic inflammation, cancer epidemiology, risk prediction, adiposity, cytokines, British Journal of Cancer